SCHEMBL8770614

SCHEMBL8770614

O=C(Nc1ccc(C(=O)c2ccc(NC(=O)c3cccs3)cc2)cc1)c1ccc(F)cc1

nearest known ligand 0.76

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.76
KMT2A Q03164 8/20 0.76
SMN1; SMN2 Q16637 3/20 0.71
HTT P42858 2/20 0.71
GAA P10253 1/20 0.71
RAB9A P51151 7/20 0.69
NPC1 O15118 6/20 0.69
TDP1 Q9NUW8 2/20 0.67
POLB P06746 1/20 0.65
MAPT P10636 4/20 0.63
LMNA P02545 2/20 0.58
GFER P55789 1/20 0.58
ALDH1A1 P00352 2/20 0.58
TP53 P04637 2/20 0.58
HPGD P15428 1/20 0.58
KCNK3 O14649 1/20 0.57
KCNK9 Q9NPC2 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8770282 0.90 MEN1 (0.85) MEN1KMT2ASMN1; SMN2HTTGAA
SCHEMBL27353966 0.90 MEN1 (0.83) MEN1KMT2ASMN1; SMN2HTTGAA
SCHEMBL8770854 0.83 PTPN1 (0.79) MEN1KMT2ASMN1; SMN2HTTRAB9A
SCHEMBL11887623 0.82 MEN1 (1.00) MEN1KMT2ASMN1; SMN2HTTRAB9A
SCHEMBL11729204 0.79 MEN1 (0.80) MEN1KMT2ASMN1; SMN2HTTGAA
SCHEMBL14082869 0.79 PTPN1 (0.67) MEN1KMT2ARAB9ANPC1TDP1
SCHEMBL13964718 0.79 MAPT (0.67) MEN1KMT2ASMN1; SMN2HTTGAA
SCHEMBL12789403 0.79 MEN1 (0.75) MEN1KMT2ASMN1; SMN2HTTGAA
SCHEMBL2074541 0.78 HPGDS (0.69) MEN1KMT2ASMN1; SMN2HTTGAA
SCHEMBL10684470 0.78 PTPN1 (0.88) MEN1KMT2ASMN1; SMN2HTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9622991-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2017-04-18 US disclosed
CN-102656141-B Micromolecular compound of simulation hemopoieticgrowth factor and uses thereof LIGAND PHARMACEUTICALS INC. (US) 2016-04-06 CN disclosed
US-9144557-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2015-09-29 US disclosed
US-20150252043-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2015-09-10 US disclosed
US-20140243324-A1 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS LIGAND PHARMACEUTICALS INCORPORATED (US) 2014-08-28 US disclosed
US-20120295904-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2012-11-22 US disclosed
WO-2012068406-A2 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS LIGAND PHARMACEUTICALS INCORPORATED (US) 2012-05-24 WO disclosed
WO-2011046954-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243324-A1 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS HGF, EPOR, MPL MEN1 1370/4885KMT2A 2225/4885SMN1; SMN2 3850/4885
US-20150252043-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES MPL, CSF3R, HGF MEN1 1395/4885KMT2A 806/4885SMN1; SMN2 941/4885
US-20120295904-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES MPL, CSF3R, HGF MEN1 1395/4885KMT2A 806/4885SMN1; SMN2 941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.